@article{oai:shiga-med.repo.nii.ac.jp:00004411,
 author = {一山, 悠介 and 松本, 理子 and 小幡, 峻平 and 澤田, 修 and 西信, 良嗣 and 柿木, 雅志 and 澤田, 智子 and 大路, 正人 and ICHIYAMA, Yusuke and MATSUMOTO, Riko and OBATA, Shumpei and SAWADA, Osamu and SAISHIN, Yoshitsugu and KAKINOKI, Masashi and SAWADA, Tomoko and OHJI, Masahito},
 issue = {12},
 journal = {PLoS ONE},
 month = {Dec},
 note = {application/pdf, Purpose:
To assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro., Methods:
In vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced retinopathy (OIR) and the effect of multiple intraperitoneal injections of ranibizumab and aflibercept on neonatal mice were assessed. In vitro, the interaction of mouse VEGF-A with aflibercept or ranibizumab as the primary antibody was analyzed by Western blot., Results:
In both experiments using intravitreal injections in OIR mice and multiple intraperitoneal injections in neonatal mice, anti-VEGF effects were observed with aflibercept, but not with ranibizumab. Western blot analysis showed immunoreactive bands for mouse VEGF-A in the aflibercept-probed blot, but not in the ranibizumab-probed blot., Conclusions:
Aflibercept but not ranibizumab interacts with mouse VEGF, both in vivo and in vitro. When conducting experiments using anti-VEGF drugs in mice, aflibercept is suitable, but ranibizumab is not., Journal Article},
 title = {Assessment of mouse VEGF neutralization by ranibizumab and aflibercept},
 volume = {17},
 year = {2022}
}